PHCCC is a Group I metabotropic glutamate receptor antagonist with EC50 of 6 uM and a positive allosteric modulator of mGluR4. Also as a potent to antagonism for mGluR2 and mGluR8. target: a Group I metabotropic glutamate receptor antagonist EC 50: 6 uM In vitro: PHCCC potentiates L-AP4-mediated inhibition of striatopallidal synaptic transmission in vitro. In vivo: 1, PHCCC produced antiparkinsonian efficacy in the reserpinized rat model means a significant level of glutamate is available for the activation of the therapeutically relevant mGluR4. 2, The reference for animal administration is 10 mg/kg.(i.p) 3,PHCCC augmentes in vivo genetic and pharmacological models of absence seizures in rats.